Novartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor
More
The pharmaceutical industry faces mounting pressure as blockbuster drug patents expire, opening markets to both generic and biosimilar competitors across the globe. Patent cliffs represent moments when brand-name drug manufacturers lose exclusivity,
More
AI tools can now access encrypted messaging platforms like iMessage, raising serious questions about confidentiality, attorney-client privilege, and discovery exposure that encryption alone cannot resolve. Businesses have long treated end-to-end encryption as
More
Consumer protection has never been a red-state or blue-state issue, yet policymakers frequently treat financial safeguards as a matter of partisan preference rather than practical necessity. When an injured consumer struggles to
More
The legal job market has strengthened considerably over the past decade, bringing welcome news for prospective students weighing the cost of a law degree. For many applicants, employment outcomes rank as the
More
The Supreme Court has determined that no party holds legal standing to challenge a president seeking to demolish a national monument without congressional approval. The ruling effectively clears a path for executive
More
A £20,000 investment spread across select FTSE 100 dividend shares could generate meaningful passive income that comfortably outpaces many high-interest savings accounts. Real estate investment trusts remain a particularly compelling option within
More
Euro zone inflation climbed back above 3% in August, driven by surging energy prices linked to the ongoing Iran war and its disruption of global supply chains. Headline inflation in the euro
More
UK borrowing costs have surged to their highest level since the financial crisis, with 10-year gilt yields rising by as much as 15 basis points on Tuesday. The benchmark 10-year gilt yield
More
Emergent BioSolutions (NYSE: EBS) is ramping up its opioid overdose education efforts across North America in recognition of International Overdose Awareness Day. The company is targeting college campuses across the United States
More